A two-week study assessing the Onset of Effect Questionnaire (OEQ) administered daily versus weekly in adult subjects
Study identifier:D5896C00023
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A two-week, randomised, double-blind study assessing the onset of Effect Questionnaire administered daily versus weekly in adult subjects (≥ 18 years) with mild to moderate asthma, receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice daily or budesonide HFA pMDI 80 μg x 2 actuations twice daily
Medical condition
asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Sex
All
Actual Enrollment
123
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Mar 2007
Primary Completion Date: -
Study Completion Date: 01 Aug 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Tomas LG Andersson
AstraZeneca
